The solutions for electrospinning were prepared using polymer (Pellethane 2363-80A (Pel-80A), Lubrizol Advanced Materials, Ritterhude, Germany), proteins (gelatin (Gel) and bivalirudin (Bv), Sigma, Missouri, MO, USA) and 1,1,1,3,3,3-hexafluoroisopropanol as a solvent in accordance to earlier described protocols [25]. To determine biocompatibility and hemocompatibility ex vivo, in vivo functioning electrospun scaffolds were produced using solutions of 3.5% Pel-80A, 3.5% Pel-80A + 10% Gel, 3.5% Pel-80A + 1.5% Bv or 3.5% Pel-80A + 10% Gel + 1.5% Bv.

The matrices (thickness = 150–160 µm) and vascular grafts (1.8 mm diameter, wall thickness = 130–150 µm) were fabricated using an NF-103 (MECC, Ogori-shi, Japan) electrospinning device under the following conditions: the feed rate 1–1.15 mL/h, capillary-collector distance 19–20 cm, voltage 18.5–24 kV, and rotation speed of drum collector 300 rpm.

The electrospun scaffolds were evacuated under forvacuum for 12 h to evaporate remaining solvent, packed with zip-lock polyethylene containers, sterilized with 25 kGy electron beam irradiation using an ILU-6 accelerator (Institute of Nuclear Physics, SB RAS), and stored at 4 °C.